



Press release 2022-08-18

Malmo, Sweden

aXichem presents promising data from clinical study regarding phenylcapsaicin's impact on serum zonulin levels and improved body weight composition in humans

[aXichem AB \(publ\) \("aXichem"\)](#), that develops and markets analogue industrial compounds, presents promising data in a peer reviewed mini review report, published in International Journal of Clinical Skills (2022) 16(7). The mini review has the title ["Placebo Controlled Study to Investigate The Relationship Between Lowering Serum Composition Using a Daily Oral Dose of Phenylcapsaicin".](#)

The report presents the promising data generated in aXichem's first clinical study, conducted at the Center for Applied Health Sciences in Canfield, Ohio, USA, in 2021, on phenylcapsaicin in humans regarding leaky gut syndrome. The result indicates that a daily intake of phenylcapsaicin, at a low dose, is likely to have a positive impact on humans with leaky gut syndrome, a syndrome associated with an imbalance in the intestinal microbiota disturbing the normal healthy gut function.

Phenylcapsaicin, at a low dose of 0.560 mg/day, lowered serum zonulin levels, from 80.78(ng/mL) to 75.50(ng/mL), after 54 days of daily oral supplementation. Lowered serum zonulin levels were correlated to improved body weight composition in the low dose treatment group but not in the high dose treatment group versus placebo in normal healthy subjects. Low dose treatment with phenylcapsaicin may be considered as a potential tool to alleviate the symptoms associated with leaky gut syndrome and commensurate healthy weight loss. The authors conclude that in further studies on phenylcapsaicin, researchers could recruit a larger and more diverse sample size to see how the compound might affect individuals of various age, ethnic or geographic cohorts. More real-world data could be gathered to determine phenylcapsaicin's effectiveness at varying levels of adherence to supplementation, changes in diet or exercise to determine the optimal dosage of the compound.

"I am very pleased that aXichem has its first promising data from an in human study regarding phenylcapsaicin and leaky gut syndrome. This report supports our sales and marketing efforts in Europe and North America in a significant way and I'm looking forward to

see follow-up studies in the future, providing more in depth knowledge and understanding for the exciting mechanisms of phenylcapsaicin", says Lucas Altepost, VP and VP of Sales and Marketing at aXichem.

About the study

The aim with the study was to evaluate the effect of phenylcapsaicin on serum levels of zonulin, weight loss and body composition changes along with diet and lifestyle modifications in healthy adults, in a randomized, double-blind, parallel-group clinical trial of male and female subjects. The aim was also to evaluate the anti-obesity effect of phenylcapsaicin on the sample population.

The study was conducted as a randomized, double-blind, parallel-group clinical trial of male and female subjects recruited at a single investigational center: the Center for Applied Health Sciences in Canfield, Ohio. The study included male and female subjects between 18 and 45 years (inclusive), with a body mass index between 27 and 35, a normal resting heart rate (<90 bpm), and normotensive. The study excluded subjects that exercised more than three times a week, as well as patients with health conditions that affected their metabolism, weight loss or gain, reproductive health, and general health conditions such as heart disease and high blood pressure. The study was conducted following ICH-GCP guidelines to ensure subject safety and scientific integrity of the data.

The information was submitted, through the care of the contact person, for publication on August 18, 2022, at 14:30 CEST.

Company contact:

Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: torsten.helsing@axichem.se

aXichem's business idea is to develop, patent and market analogue industrial compounds. The Company primarily works with phenylcapsaicin, a structural analogue of capsaicin with a wide range of applications, such as feed additives, marine anti-fouling products and certain pharmaceutical areas. aXichem's shares are listed on NASDAQ First North under AXIC A. Certified Adviser: Redeye AB Certifiedadviser@redeye.se +46 (0)8 121 576 90. Read more about the company at www.axichem.se

aXichem AB • Södergatan 26 • 211 34 Malmö, Sweden • P: +46 46 780 06 73 • post@axichem.se